Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Abstract:There is no standard therapy for patients with myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMA) and the median overall survival (OS) of HMA-refractory MDS patients with IPSS Intermediate-2/High-risk MDS is ~6 months. Here, we present data from a phase 2 clinical trial of selinexor, an oral, first-in-class Selective Inhibitor of Nuclear Export (SINE) compound that inhibits XPO1, in patients with MDS refractory to HMAs. XPO1 is the major nuclear export protein responsible for shuttling … Show more
“…Patients with HR-MDS and those who fail to respond to or to relapse/ progress after HMA treatment have limited therapeutic options and poor prognosis [18]. The median overall survival of HMA refractory MDS with IPSS intermediate-2/ high risk MDS was ~6 months [19]. There is no approved second-line therapy [11].…”
“…Patients with HR-MDS and those who fail to respond to or to relapse/ progress after HMA treatment have limited therapeutic options and poor prognosis [18]. The median overall survival of HMA refractory MDS with IPSS intermediate-2/ high risk MDS was ~6 months [19]. There is no approved second-line therapy [11].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.